newsfilter
← Latest News
ACCESS Newswire·

Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients

TORONTO, ON / ACCESSWIRE / February 3, 2022 / Novamind Inc. (CSE:NM, OTCQB:NVMDF, FSE:HN2))) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected by the Ketamine Research